Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Kivu Bioscience Inc.
Seagen Inc.
Tizona Therapeutics, Inc
Dana-Farber Cancer Institute
Normunity AccelCo, Inc.
IDEAYA Biosciences
MacroGenics
SystImmune Inc.
Solve Therapeutics
Fusion Pharmaceuticals Inc.
GlaxoSmithKline
Fate Therapeutics
NeoTX Therapeutics Ltd.
West China Hospital
Incyte Corporation
M.D. Anderson Cancer Center
Tempest Therapeutics
Exelixis
Totus Medicines
Theratechnologies
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
Acepodia Biotech, Inc.
Xencor, Inc.
Prelude Therapeutics
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
MacroGenics
Eisai Inc.
Critical Outcome Technologies Inc.
Merrimack Pharmaceuticals
Santa Maria Biotherapeutics
BIND Therapeutics
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Pharmacyclics LLC.